Allist(SH:688578)2025-04-23 11:15Financial Performance - The company's revenue for Q1 2025 reached ¥1,098,374,566.26, representing a 47.86% increase compared to ¥742,835,715.09 in the same period last year[4] - Net profit attributable to shareholders was ¥410,497,438.67, a 34.13% increase from ¥306,052,559.16 year-on-year[4] - Basic and diluted earnings per share increased to ¥0.91, reflecting a growth of 33.82% compared to ¥0.68 in the prior year[4] - Operating profit for Q1 2025 was RMB 477,078,629.83, compared to RMB 313,917,428.44 in Q1 2024, reflecting a 52.0% increase[21] - Total comprehensive income for Q1 2025 was RMB 346,738,605.88, slightly up from RMB 320,044,154.27 in Q1 2024[22] Research and Development - R&D investment totaled ¥112,129,230.35, up 74.86% from ¥64,126,011.92 in the previous year, accounting for 10.21% of revenue[4] - The company experienced a 43.08% increase in R&D expenses, driven by new clinical projects for Vomeprazole[7] - Research and development expenses increased to RMB 91,754,053.37 in Q1 2025, up 43.3% from RMB 64,126,011.92 in Q1 2024[21] - The company is advancing its clinical research with a newly approved Phase III trial for Furmetin, targeting non-small cell lung cancer patients with non-classical EGFR mutations[14] - The company is committed to developing innovative drugs to meet unmet clinical needs, focusing on First-in-class and Best-in-class therapies[14] Assets and Liabilities - The total assets at the end of the reporting period were ¥6,234,673,159.21, a 5.38% increase from ¥5,916,131,448.10 at the end of the previous year[5] - Total assets as of March 31, 2025, amounted to RMB 6.235 billion, an increase from RMB 5.916 billion at the end of 2024[19] - The total liabilities decreased to RMB 597.48 million from RMB 633.32 million in the previous period[19] - The company’s retained earnings increased to RMB 1.621 billion, up from RMB 1.245 billion at the end of 2024[19] Cash Flow - The net cash flow from operating activities was ¥392,806,950.89, a 7.54% increase from ¥365,255,516.58 in the previous year[4] - Cash flow from operating activities for Q1 2025 was RMB 392,806,950.89, compared to RMB 365,255,516.58 in Q1 2024, indicating a positive trend[24] - The company reported a net cash outflow from investing activities of RMB -581,527,811.19 in Q1 2025, compared to a net inflow of RMB 468,725,625.83 in Q1 2024[24] - The company's cash and cash equivalents stood at RMB 588.61 million, slightly up from RMB 586.99 million at the end of the previous year[17] - Cash and cash equivalents at the end of Q1 2025 were RMB 333,136,530.30, down from RMB 1,917,563,295.01 at the end of Q1 2024[26] Marketing and Sales - The company reported a significant increase in sales expenses by 44.65% due to an expanded marketing team and promotional activities for its product, Vomeprazole[7] - The core product, Furmetin (甲磺酸伏美替尼片), saw continuous sales growth, benefiting an expanding patient population in China[13] - The marketing team is actively promoting the RET inhibitor Pralsetinib (普吉华○R), leveraging synergies from Furmetin's market development[13] - Total operating costs for Q1 2025 were RMB 641,306,439.50, an increase of 47.8% from RMB 433,988,956.35 in Q1 2024[21] Government Support - The company received government subsidies amounting to ¥2,294,972.60, contributing to a 165.26% increase in other income[6]